Literature DB >> 8741308

Clinical features of measles in immunocompromised children.

T Nakano1, Y Shimono, K Sugiyama, H Nishihara, M Higashigawa, Y Komada, M Ito, M Sakurai, A Yoshida, K Kitamura, T Ihara, H Kamiya, M Hamazaki, T Sata.   

Abstract

Measles is often fatal for immunocompromised hosts. Protective immunity against measles has been studied but is still not completely understood. Recently, five cases of measles were encountered in immunocompromised children. Two of these were allogeneic bone marrow transplanted cases (one common variable immunodeficiency and one severe aplastic anemia) in remission, one Wilms' tumor case in remission, one hepatoblastoma case after cytotoxic therapy at disease onset and one exaggerating hemophagocytic syndrome case with suppressed natural killer cell activity. Clinical symptoms, laboratory findings and the immunologic backgrounds of these five patients were investigated. One of the patients, an 8 year old boy with hemophagocytic syndrome, died of giant cell pneumonia which was confirmed in the section of necropsy lung specimen. Two other patients who received allogeneic bone marrow transplants were not immune to measles, despite their own and their donors' immunizations. Their clinical symptoms were rather severe but both patients recovered and have remained seropositive for as long as 13 months. This fatality from measles is the first reported in a patient with hemophagocytic syndrome. Suppressed natural killer cell activity may be a poor prognostic factor. Also, secondary immunization failure for measles can occur in bone marrow transplanted patients with rather severe clinical symptoms.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8741308     DOI: 10.1111/j.1442-200x.1996.tb03472.x

Source DB:  PubMed          Journal:  Acta Paediatr Jpn        ISSN: 0374-5600


  7 in total

1.  Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.

Authors:  Marcie Tomblyn; Tom Chiller; Hermann Einsele; Ronald Gress; Kent Sepkowitz; Jan Storek; John R Wingard; Jo-Anne H Young; Michael J Boeckh; Michael A Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2009-10       Impact factor: 5.742

Review 2.  Infectious complications and vaccines.

Authors:  Per Ljungman
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

3.  Measles and secondary hemophagocytic lymphohistiocytosis.

Authors:  Chiara Iaria; Maria Silvana Leonardi; Agata Buda; Maria Luisa Toro; Antonio Cascio
Journal:  Emerg Infect Dis       Date:  2012-09       Impact factor: 6.883

Review 4.  Viral infections in immunocompromised patients.

Authors:  Janet Englund; Tobias Feuchtinger; Per Ljungman
Journal:  Biol Blood Marrow Transplant       Date:  2011-01       Impact factor: 5.742

5.  Measles Outbreak in Pediatric Hematology and Oncology Patients in Shanghai, 2015.

Authors:  Yan-Ling Ge; Xiao-Wen Zhai; Yan-Feng Zhu; Xiang-Shi Wang; Ai-Mei Xia; Yue-Fang Li; Mei Zeng
Journal:  Chin Med J (Engl)       Date:  2017-06-05       Impact factor: 2.628

6.  Safety of Live-Attenuated Measles, Mumps, and Rubella Vaccine Administered Within 2 Years of Hematopoietic Cell Transplant.

Authors:  Michaël Desjardins; Xhoi Mitre; Amy C Sherman; Stephen R Walsh; Matthew P Cheng; Sanjat Kanjilal; Vincent T Ho; Lindsey R Baden; Nicolas C Issa
Journal:  Open Forum Infect Dis       Date:  2021-11-23       Impact factor: 3.835

7.  Immunohistochemical detection of virus through its nuclear cytopathic effect in idiopathic interstitial pneumonia other than acute exacerbation.

Authors:  G C Dos Santos; E R Parra; F W Stegun; C S Cirqueira; V L Capelozzi
Journal:  Braz J Med Biol Res       Date:  2013-11-18       Impact factor: 2.590

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.